VITROS IMMUNODIAGNOSTIC PRODUCTS ANTI-HBC IGM REAGENT PAK/CALIBRATOR

Test, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)

FDA Premarket Approval P030026

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the vitros immunodiagnostic products anti-hbc igm reagent pack and vitros immunodiagnostic products anti-hbc igm calibrator. These devices are indicated for: 1) vitros immunodiagnostic products anti-hbc igm reagent pack is indicated for the in vitro qualitative detection of igm antibody to hepatitis b core antigen (anti-hbc igm) in human adult and pediatric serum and plasma (heparin, edta and citrate) and neonate serum using the vitros eci immunodiagnostic system. Assay results, in conjunction with other serological and clinical information, may be used for the laboratory diagnosis of individuals with acute or chronic hepatitis b. 2) vitros immunodiagnostic products anti-hbc igm calibrator is indicated for the use in the calibration of the vitros immunodiagnostic system for the in vitro qualitative detection of igm antibody to hepatitis b core antigen (anti-hbc igm) in human adult and pediatric serum and plasma (edta, heparin or citrate) and neonate serum using vitro anti-hbc igm reagent packs.

DeviceVITROS IMMUNODIAGNOSTIC PRODUCTS ANTI-HBC IGM REAGENT PAK/CALIBRATOR
Classification NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
Generic NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
ApplicantOrtho-Clinical Diagnostics, Inc.
Date Received2003-06-27
Decision Date2004-03-04
Notice Date2004-08-09
PMAP030026
SupplementS
Product CodeLOM
Docket Number04M-0356
Advisory CommitteeMicrobiology
Expedited ReviewNo
Combination Product No
Applicant Address Ortho-Clinical Diagnostics, Inc. 100 Indigo Creek Dr. rochester, NY 14626-5101
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P030026Original Filing
S037 2022-09-30 Real-time Process
S036 2019-05-21 30-day Notice
S035 2018-10-16 Normal 180 Day Track No User Fee
S034 2018-02-21 Normal 180 Day Track No User Fee
S033 2018-01-16 30-day Notice
S032 2018-01-09 Normal 180 Day Track No User Fee
S031 2015-10-05 30-day Notice
S030 2015-08-10 30-day Notice
S029 2015-01-16 30-day Notice
S028 2013-09-20 30-day Notice
S027 2012-11-29 30-day Notice
S026 2012-10-17 30-day Notice
S025 2012-01-30 30-day Notice
S024 2011-10-05 Real-time Process
S023 2011-05-19 30-day Notice
S022 2011-05-16 135 Review Track For 30-day Notice
S021 2010-12-08 30-day Notice
S020 2010-10-18 30-day Notice
S019 2009-12-01 Normal 180 Day Track No User Fee
S018 2009-05-22 30-day Notice
S017 2009-03-06 30-day Notice
S016 2009-02-20 Normal 180 Day Track
S015 2008-11-13 Normal 180 Day Track No User Fee
S014 2008-02-27 30-day Notice
S013 2007-03-08 30-day Notice
S012 2007-02-07 Special (immediate Track)
S011 2006-08-21 30-day Notice
S010 2006-05-17 30-day Notice
S009 2005-11-14 30-day Notice
S008 2005-09-30 Special (immediate Track)
S007 2005-06-27 30-day Notice
S006 2005-06-03 30-day Notice
S005 2005-04-07 30-day Notice
S004 2004-12-21 30-day Notice
S003 2004-12-15 30-day Notice
S002 2004-10-26 30-day Notice
S001 2004-05-24 30-day Notice

NIH GUDID Devices

Device IDPMASupp
10758750002795 P030026 028
10758750001194 P030026 028
10758750001187 P030026 028

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.